ImmuneRegen BioSciences, Inc. Demonstrates That Viprovex(TM) Is a Potential Treatment for Avian and Other Influenzas
09 Januar 2007 - 1:00PM
PR Newswire (US)
SCOTTSDALE, Ariz., Jan. 9 /PRNewswire-FirstCall/ -- ImmuneRegen
BioSciences, a wholly owned subsidiary of IR BioSciences Holdings,
Inc. (OTC:IRBO) (BULLETIN BOARD: IRBO) , today announced results
from tests conducted using Viprovex(TM), its proprietary compound,
in a severe influenza treatment study. Tests evaluating
ImmuneRegen's Viprovex(TM) as a measure in the possible treatment
of influenza virus infection were conducted at Virion Systems, Inc.
(VSI), a Maryland biotechnology corporation. Influenza studies were
performed using a cotton rat (Sigmodon hispidus) model system with
the influenza A/Wuhan/359/95 (H3N2), a robust, peer-reviewed model
system for studying human influenza. Management believes that
preliminary results of Viprovex treatment of cotton rats infected
with the H3N2/Wuhan human influenza virus provided indications that
Viprovex may have positive effects on enhancing immunity against
influenza infection and supports ongoing development of Viprovex as
a potential treatment for seasonal influenza. Viprovex treatment
reduced nasal and lung titers one- to two- logs (90+ %) compared to
infected but untreated controls. In addition, treated animals
appeared to lose less weight than untreated infected animals and
appeared to regain normal body weight more rapidly. Additionally,
Viprovex treated animals appeared to have less change in body
temperature then untreated animals. Company officials believe that
the preliminary data suggests that Viprovex could have positive
effects in the treatment of influenza infection perhaps through the
modulation of cytokine activation and in the enhancement of innate
immunity to influenza. Additional studies are presently underway in
this and other influenza model systems to confirm and expand these
results. About Virion Systems, Inc. Virion Systems, Inc. is a
Maryland biotechnology corporation focused on the prevention and
treatment of infectious diseases, particularly those involving
infants and children. Its core technology is the use of the cotton
rat as an animal model of human infectious diseases. VSI performs
contract research for academic and commercial groups, centered
around the use of the cotton rat. In addition to research on
prevention and treatment of infectious diseases, VSI also conducts
contract research involving the use of adenoviruses as vectors for
genetic therapy, as the cotton rat is the only small animal
permissive for human adenoviruses. About ImmuneRegen BioSciences,
Inc. IR BioSciences Holdings Inc., through its wholly owned
subsidiary ImmuneRegen BioSciences, Inc., is a development stage
biotechnology company focused on the research and development of
Homspera(TM) and its derivatives Radilex(TM) and Viprovex(TM),
which are designed to be used as countermeasures for multiple
homeland security bioterrorism threats. Homspera is derived from
modified Substance P, a naturally occurring peptide immunomodulator
and homeostatic compound with the dual effect of improving
pulmonary function and the stimulation of the human immune system.
For more information, please visit the company's website at
http://www.immuneregen.com/. Statements about the Company's future
expectations, including statements about the potential for the
Company's drug candidates, science and technology, and all other
statements in this press release other than historical facts, are
"forward-looking statements" within the meaning of Section 27A of
the Securities Act of 1933, Section 21E of the Securities Exchange
Act of 1934, and as that term is defined in the Private Securities
Litigation Reform Act of 1995. The Company intends that such
forward-looking statements be subject to the safe harbors created
thereby. These future events may not occur as and when expected, if
at all, and, together with the Company's business, are subject to
various risks and uncertainties. The Company's actual results could
differ materially from expected results as a result of a number of
factors, including the fact that preliminary results involved only
a small number of test mice, the subsequent investigations were
limited in scope, the uncertainties inherent in research and
development collaborations, pre- clinical and clinical trials and
product development programs, (including, but not limited to the
fact that future results or research and development efforts may
prove less encouraging than current results or cause side effects
not observed in current pre-clinical trials) the evaluation of
potential opportunities, the level of corporate expenditures and
monies available for further studies, capital market conditions,
and others set forth in the Company's periodic report on Form
10-QSB for the three months ended September 30, 2006 and on Form
10-KSB for the twelve months ended December 31, 2005 as filed with
the Securities and Exchange Commission. There are no guarantees
that any of the Company's proposed products will prove to be
commercially successful. The Company undertakes no duty to update
forward- looking statements. MEDIA CONTACT: W. Jason Grimley
Spelling Communications 310-477-9500 INVESTOR CONTACT: Josh
Reynolds CEOcast, Inc. 212-732-4300 DATASOURCE: ImmuneRegen
BioSciences CONTACT: Media, W. Jason Grimley of Spelling
Communications, +1-310-477-9500, , for ImmuneRegen BioSciences; or
Investors, Josh Reynolds of CEOcast, Inc., +1-212-732-4300, , for
ImmuneRegen BioSciences Web site: http://www.immuneregen.com/
Copyright